Indegene Cortex & NEXT: Platform Primer

AI Solutions Strategist – Medical Writing · Indegene (client, via Zodiac Solutions → Mapout Digital)
Round 1 · 2026-07-29

1. The Platform Stack

  • Cortex — Indegene's proprietary GenAI platform: a "life sciences-specialist knowledge engineering and multi-agent orchestration platform." Launched Feb 24, 2025. Codifies 25+ years of Indegene subject-matter expertise into knowledge graphs. Explicitly LLM-agnostic — agents configurable with any preferred model; no specific model named publicly.
  • NEXT Medical Writing Automation — launched Jul 11, 2025, built on Cortex. Auto-generates compliant document drafts inside Microsoft Word; adapts to sponsor-specific formats/workflows; integrates with RIM (Regulatory Information Management) systems for traceability; adds automated scheduling/task assignment.
    Sameer Lal (SVP Enterprise Medical Solutions): “We see this platform as more than automation — it's about elevating the entire practice of medical writing.”
  • NEXT MLR Review Automation — companion product; agentic AI for medical-legal-regulatory review. Shows the NEXT suite spans the full regulatory content lifecycle, not just writing.
  • Seed technology — Indegene acquired Trilogy Writing & Consulting GmbH (Germany/UK/US, 22+ years clinical/regulatory/safety medical writing) on Mar 27, 2024, explicitly to combine Trilogy's writing depth with Indegene's GenAI scalability. Trilogy already had its own AI-enabling writing technology pre-acquisition — very likely the seed for NEXT.

2. Cloud & Infrastructure

  • Multi-cloud, not single-vendor.
  • Microsoft strategic collaboration announced Jul 11, 2024: Azure OpenAI Service; Microsoft Copilot deployed to 5,000+ employees; Microsoft Fabric for clinical trial data ingestion/governance.
  • AWS confirmed separately via a published AWS case study (Jun 12, 2025) covering NEXT's production hosting and observability — CloudWatch Synthetics, RUM, Alarms.
  • Veeva is a client-side integration target (DAM, likely Vault PromoMats-adjacent) — not Indegene's own authoring platform. NEXT pushes content into client-owned Veeva systems; it does not replace them.

3. Not Publicly Confirmed — Ask in the Room

  • Underlying LLM(s): none named by design (Cortex is model-agnostic). Ask which model(s) this specific engagement actually uses.
  • RIM/DAM vendor: not confirmed for this client. Ask directly — Veeva Vault or something else?
  • Regulatory framework: no FDA/EMA/ICH framework named anywhere public — compliance language stays generic ("compliant drafts," "governance," "traceability"). Ask which framework the actual client operates under.
  • Adoption maturity: no case count, therapeutic area, or client reference for NEXT beyond the launch announcement. FY26 investor materials give more disclosed revenue traction to Tectonic (commercial/marketing platform, $2M H1 revenue, 4 customers) than to NEXT specifically — probe how mature NEXT's actual client adoption is.
  • Org placement: ask which named client account or "Strategic Tier" engagement this seat serves, and whether it reports into Sameer Lal's Enterprise Medical Solutions org — reveals whether this is delivery on an existing NEXT engagement or a new client stand-up.

4. How to Position

  • John has not personally operated Cortex or NEXT — but his own architecture is functionally identical.
  • NewsRx runs a self-hosted, model-swappable pipeline (vLLM / Qwen3-32B, easily reconfigured to any model) — the same "LLM-agnostic" design principle as Cortex.
  • Generates governed content with traceability — ALCOA+ audit trail, 21 CFR Part 11 electronic signatures — analogous to NEXT's RIM-integration traceability claim.
Say this: “I haven't operated Cortex specifically, but I've built and operated the same architectural pattern in production — model-agnostic orchestration, source-grounded generation, audit-trail traceability — so the learning curve is about your specific configuration, not the underlying discipline.”
← Back to index